Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy

G. Filaci, M. Cutolo, M. Scudeletti, C. Castagneto, L. Derchi, R. Gianrossi, F. Ropolo, P. Zentilin, A. Sulli, G. Murdaca, M. Ghio, F. Indiveri, F. Puppo

Research output: Contribution to journalArticle

Abstract

Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment. Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects. Results. After 1 yr of therapy, a significant improvement of skin (P = 0.008), microvascular (P = 0.004) and oesophageal (P = 0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P = 0.007) of IL-6 serum concentration was observed only in Group II patients. Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production.

Original languageEnglish
Pages (from-to)992-996
Number of pages5
JournalRheumatology
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 1999

Fingerprint

Iloprost
Systemic Scleroderma
Cyclosporine
Interleukin-6
Serum
Therapeutics
Therapeutic Uses
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Clinical Trials
Skin

Keywords

  • Cyclosporin A
  • Iloprost
  • Interleukin 6
  • Systemic sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Cite this

Cyclosporin A and iloprost treatment of systemic sclerosis : Clinical results and interleukin-6 serum changes after 12 months of therapy. / Filaci, G.; Cutolo, M.; Scudeletti, M.; Castagneto, C.; Derchi, L.; Gianrossi, R.; Ropolo, F.; Zentilin, P.; Sulli, A.; Murdaca, G.; Ghio, M.; Indiveri, F.; Puppo, F.

In: Rheumatology, Vol. 38, No. 10, 10.1999, p. 992-996.

Research output: Contribution to journalArticle

Filaci, G, Cutolo, M, Scudeletti, M, Castagneto, C, Derchi, L, Gianrossi, R, Ropolo, F, Zentilin, P, Sulli, A, Murdaca, G, Ghio, M, Indiveri, F & Puppo, F 1999, 'Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy', Rheumatology, vol. 38, no. 10, pp. 992-996. https://doi.org/10.1093/rheumatology/38.10.992
Filaci, G. ; Cutolo, M. ; Scudeletti, M. ; Castagneto, C. ; Derchi, L. ; Gianrossi, R. ; Ropolo, F. ; Zentilin, P. ; Sulli, A. ; Murdaca, G. ; Ghio, M. ; Indiveri, F. ; Puppo, F. / Cyclosporin A and iloprost treatment of systemic sclerosis : Clinical results and interleukin-6 serum changes after 12 months of therapy. In: Rheumatology. 1999 ; Vol. 38, No. 10. pp. 992-996.
@article{0beabf57586549189264fcf9fa8e3619,
title = "Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy",
abstract = "Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment. Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects. Results. After 1 yr of therapy, a significant improvement of skin (P = 0.008), microvascular (P = 0.004) and oesophageal (P = 0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P = 0.007) of IL-6 serum concentration was observed only in Group II patients. Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production.",
keywords = "Cyclosporin A, Iloprost, Interleukin 6, Systemic sclerosis",
author = "G. Filaci and M. Cutolo and M. Scudeletti and C. Castagneto and L. Derchi and R. Gianrossi and F. Ropolo and P. Zentilin and A. Sulli and G. Murdaca and M. Ghio and F. Indiveri and F. Puppo",
year = "1999",
month = "10",
doi = "10.1093/rheumatology/38.10.992",
language = "English",
volume = "38",
pages = "992--996",
journal = "Rheumatology",
issn = "1462-0324",
publisher = ". Published by Oxford University Press on behalf of the British Society for Rheumatology",
number = "10",

}

TY - JOUR

T1 - Cyclosporin A and iloprost treatment of systemic sclerosis

T2 - Clinical results and interleukin-6 serum changes after 12 months of therapy

AU - Filaci, G.

AU - Cutolo, M.

AU - Scudeletti, M.

AU - Castagneto, C.

AU - Derchi, L.

AU - Gianrossi, R.

AU - Ropolo, F.

AU - Zentilin, P.

AU - Sulli, A.

AU - Murdaca, G.

AU - Ghio, M.

AU - Indiveri, F.

AU - Puppo, F.

PY - 1999/10

Y1 - 1999/10

N2 - Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment. Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects. Results. After 1 yr of therapy, a significant improvement of skin (P = 0.008), microvascular (P = 0.004) and oesophageal (P = 0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P = 0.007) of IL-6 serum concentration was observed only in Group II patients. Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production.

AB - Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment. Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects. Results. After 1 yr of therapy, a significant improvement of skin (P = 0.008), microvascular (P = 0.004) and oesophageal (P = 0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P = 0.007) of IL-6 serum concentration was observed only in Group II patients. Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production.

KW - Cyclosporin A

KW - Iloprost

KW - Interleukin 6

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=6544229063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6544229063&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/38.10.992

DO - 10.1093/rheumatology/38.10.992

M3 - Article

C2 - 10534551

AN - SCOPUS:6544229063

VL - 38

SP - 992

EP - 996

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 10

ER -